Gene Techno Science Co., Ltd.
Records under this name other than the patents Gene Techno Science Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 10 of 10 · Back to Gene Techno Science Co., Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,544,466 | Method for diagnosing and treating cancer brain metastasis and drug delivery system for enabling passage through blood-brain barrier Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,595,045 | Anti-α9 integrin antibody and the use thereof Term ended Term ended Mar 22, 2026 · From the USPTO record | Term ended | Term ended Mar 22, 2026 | From the USPTO record |
| US 8,372,639 | Anti-human α9 integrin antibody and use thereof Lapsed on the fee record Ended Feb 12, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 12, 2025 | From the USPTO record |
| US 10,774,312 | Method for producing frozen mesenchymal cells and method for producing implantable therapeutic member Lapsed on the fee record Ended Sep 15, 2024 · From the USPTO record | Lapsed on the fee record | Ended Sep 15, 2024 | From the USPTO record |
| US 8,221,754 | Antihuman α9 integrin antibody and use of the same Lapsed on the fee record Ended Jul 17, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jul 17, 2024 | From the USPTO record |
| US 8,821,863 | Humanized anti-α 9 integrin antibodies and the uses thereof Lapsed on the fee record Ended Sep 2, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 2, 2022 | From the USPTO record |
| US 8,735,552 | Generation, expression and characterization of the humanized K33N monoclonal antibody Lapsed on the fee record Ended May 27, 2022 · From the USPTO record | Lapsed on the fee record | Ended May 27, 2022 | From the USPTO record |
| US 8,617,829 | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof Lapsed on the fee record Ended Dec 31, 2021 · From the USPTO record | Lapsed on the fee record | Ended Dec 31, 2021 | From the USPTO record |
| US 8,614,296 | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof Lapsed on the fee record Ended Dec 24, 2021 · From the USPTO record | Lapsed on the fee record | Ended Dec 24, 2021 | From the USPTO record |
| US 8,461,310 | Anti-Adam-15 Antibodies and Utilization of the Same Lapsed on the fee record Ended Jun 11, 2021 · High confidence | Lapsed on the fee record | Ended Jun 11, 2021 | High confidence |